Stress Linked to Mortality in Cervical Cancer
Researchers sought to identify the potential influence of stress-related psychiatric disorders and stressful life events on cancer-specific mortality in women with cervical cancer.
Cervical Cancer
Higher Surgical Volume May Improve Outcomes in Cervical Cancer
Findings show radical hysterectomy at high-volume centers tied to better survival in early cervical cancer.
Some Cervical Cancer Screening Strategies More Cost-Effective
Most lifetime QALYs seen with cytologic testing every 3 years, repeated for ASC-US.
CDC: Recent Decline Seen in High-Grade Cervical Lesions
Vast majority of cervical precancer cases attributable to HPV types targeted by 9-valent HPV vaccine
Decline Observed in HPV Type 16/18 Cervical Precancers in US
The proportion of human papillomavirus (HPV) 16/18-positive cervical intraepithelial neoplasia grades 2 to 3 or adenocarcinoma in situ (CIN2+) declined from 2008 to 2014.
44.4 Million Estimated to Be Diagnosed With Cervical Cancer by 2069
In the absence of further intervention, in the next 50 years, an estimated 44.4 million women will be diagnosed with cervical cancer globally.
Self-Sampling Strategy to Encourage Screening for High-Risk Human Papillomavirus
Women who used a self-screening assay for high-risk human papillomavirus had similar test results to those who were screened by a clinician.
HPV Screening Associated With Reduced Remaining Lifetime Cervical Cancer Risk in Older Women
Researchers determined that women ≥55 years of age who underwent a single HPV DNA test with a negative diagnosis as well as routine cytology were found to be at low risk for cervical cancer.
Positive HPV Status Tied to Better Cervical Cancer Prognosis
Women with high-risk human papillomavirus-positive cervical tumors have a substantially better prognosis than women with hrHPV-negative tumors.
HPV Vaccination Decreases High-Grade Cervical Lesions in Women
From 2008 to 2015, both cervical intraepithelial neoplasia grades 2, 3 and adenocarcinoma in situ rates and cervical cancer screening declined in women age 18 to 24 years.
